DBV Technologies S.A. - 20-F Filing Summary (Year Ended Dec 31, 2015)
Business Context and Reporting Period
Company: DBV Technologies S.A.
Reporting Period: Fiscal year ended December 31, 2015
Business Model: Clinical-stage biopharmaceutical company developing epicutaneous immunotherapy (EPIT) via the Viaskin platform to treat severe food allergies. The company has no approved products for commercial sale and relies on equity financing and government grants.
Key Milestone: Initiated the pivotal Phase III PEPITES trial for Viaskin Peanut in December 2015. Discontinued sales of its diagnostic product, Diallertest Milk, in the second half of 2015.
Key Financial Metrics
| Metric (in thousands, EUR) | 2015 | 2014 |
|---|---|---|
| Operating Income | 6,166 | 4,762 |
| Operating Expenses | 51,712 | 29,397 |
| Operating Loss | (45,546) | (24,636) |
| Net Loss | (44,674) | (24,012) |
| Loss Per Share (Basic/Diluted) | (2.08) | (1.49) |
| Cash and Cash Equivalents | 323,381 | 114,583 |
| Total Assets | 343,280 | 125,416 |
| Total Liabilities | 21,204 | 9,971 |
| Shareholders' Equity | 322,076 | 115,445 |
Note: Operating income is primarily derived from the French Research Tax Credit (CIR) and government subsidies, not product sales. Revenues from Diallertest Milk were negligible (€202k) and ceased in late 2015.
Material Changes vs. Prior Period
- Revenue & Income: Operating income increased 29.5% to €6.2 million, driven by a 31% increase in the Research Tax Credit (CIR) to €5.7 million. Product revenues declined 4.1% to €202k before cessation.
- Expenses: Total operating expenses surged 76% to €51.7 million.
- R&D: Increased 62% to €34.2 million due to the initiation of the Phase III PEPITES trial, expansion of the MILES trial for Viaskin Milk, and a 72% increase in R&D personnel (from 42 to 72 employees).
- G&A: Doubled to €16.9 million, driven by a 263% increase in professional fees (audit, legal, compliance) and a 438% increase in insurance costs related to Nasdaq listing and Sarbanes-Oxley compliance.
- Sales & Marketing: Increased from €13k to €491k as the company hired initial staff for North American commercialization.
- Liquidity: Cash position more than tripled to €323.4 million following a €255.3 million public offering in July 2015. Net cash provided by financing activities was €241.0 million.
Guidance, Outlook, and Risks
- Outlook: Management expects existing cash to fund operations until the end of 2017. The company anticipates continued significant losses as it advances clinical trials and prepares for potential commercialization.
- Clinical Pipeline:
- Viaskin Peanut: PEPITES Phase III trial (ages 4-11) initiated Dec 2015; results expected H2 2017.
- Viaskin Milk: MILES Phase I/II trial ongoing; results expected H2 2017.
- Viaskin Egg: Pre-clinical development underway.
- Material Weakness in Internal Controls: The company identified a material weakness in internal control over financial reporting for 2015 due to a lack of adequate segregation of duties within the finance team. Remediation efforts are underway, including hiring additional staff and engaging external advisors.
- Risks: Significant risks include the failure of clinical trials, inability to obtain regulatory approval, dependence on third-party manufacturers (Sanofi), and the need for additional capital if cash reserves are depleted sooner than expected.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the "end of 2017" funding estimate given the rapid increase in operating expenses (€51.7M in 2015).
- Internal Controls: Monitor progress on remediation of the identified material weakness in financial reporting to ensure future compliance with Sarbanes-Oxley Act Section 404.
- Clinical Trial Enrollment: Track enrollment rates for the PEPITES Phase III trial, as delays could significantly impact the timeline for regulatory filing.
- Government Grants: Assess the sustainability of the Research Tax Credit (CIR), which constituted the vast majority of operating income (€5.7M of €6.2M).
- Manufacturing Scalability: Confirm the readiness of the GEN4.0 manufacturing tool (expected H2 2016) to support commercial-scale production if approval is granted.